ATE389399T1 - Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum - Google Patents

Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum

Info

Publication number
ATE389399T1
ATE389399T1 AT04797529T AT04797529T ATE389399T1 AT E389399 T1 ATE389399 T1 AT E389399T1 AT 04797529 T AT04797529 T AT 04797529T AT 04797529 T AT04797529 T AT 04797529T AT E389399 T1 ATE389399 T1 AT E389399T1
Authority
AT
Austria
Prior art keywords
diuretic
amiloride
triamterin
valsartan
combinations
Prior art date
Application number
AT04797529T
Other languages
English (en)
Inventor
Daniel Vasella
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29725841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE389399(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE389399T1 publication Critical patent/ATE389399T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04797529T 2003-11-03 2004-11-02 Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum ATE389399T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0325605.4A GB0325605D0 (en) 2003-11-03 2003-11-03 Combination of organic compounds

Publications (1)

Publication Number Publication Date
ATE389399T1 true ATE389399T1 (de) 2008-04-15

Family

ID=29725841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04797529T ATE389399T1 (de) 2003-11-03 2004-11-02 Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum

Country Status (16)

Country Link
US (2) US20070072848A1 (de)
EP (1) EP1682122B9 (de)
JP (1) JP2007509900A (de)
KR (1) KR20060097025A (de)
CN (1) CN1878548A (de)
AT (1) ATE389399T1 (de)
AU (1) AU2004290505B2 (de)
BR (1) BRPI0416154A (de)
CA (1) CA2544230A1 (de)
DE (1) DE602004012593T2 (de)
ES (1) ES2303958T3 (de)
GB (1) GB0325605D0 (de)
PL (1) PL1682122T3 (de)
PT (1) PT1682122E (de)
RU (1) RU2006119329A (de)
WO (1) WO2005049013A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
WO2012152718A1 (en) 2011-05-06 2012-11-15 Farmicom Pharmaceutical Company D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
CN102793703A (zh) * 2011-05-25 2012-11-28 苏州洪瑞医药科技有限公司 一种盐酸阿米洛利和环戊噻嗪的药物组合物及其制备方法
WO2018027550A1 (en) * 2016-08-09 2018-02-15 Shanghai Yao Yuan Biotechnology Co., Ltd. Methods and compositions for appetite control and weight management
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JP2004514703A (ja) * 2000-12-01 2004-05-20 ノバルティス　アクチエンゲゼルシャフト 有機化合物の組合せ剤
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
AU2004290505A1 (en) 2005-06-02
US20090036432A1 (en) 2009-02-05
CA2544230A1 (en) 2005-06-02
DE602004012593T2 (de) 2009-04-23
US20070072848A1 (en) 2007-03-29
ES2303958T3 (es) 2008-09-01
EP1682122B9 (de) 2009-04-08
EP1682122A1 (de) 2006-07-26
PL1682122T3 (pl) 2008-09-30
PT1682122E (pt) 2008-06-18
AU2004290505B2 (en) 2007-09-20
DE602004012593D1 (de) 2008-04-30
JP2007509900A (ja) 2007-04-19
CN1878548A (zh) 2006-12-13
KR20060097025A (ko) 2006-09-13
GB0325605D0 (en) 2003-12-10
RU2006119329A (ru) 2007-12-27
WO2005049013A1 (en) 2005-06-02
EP1682122B1 (de) 2008-03-19
BRPI0416154A (pt) 2007-01-09

Similar Documents

Publication Publication Date Title
UY27720A1 (es) Aroilpiridinonas monocíclicas,
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
SE0301653D0 (sv) Novel compounds
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
WO2004103390A3 (en) Stable analogs of peptide and polypeptide therapeutics
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
BR0317555A (pt) Composições farmacêuticas de sertaconazol para uso vaginal
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
UY28312A1 (es) Pirazolopirimidinas sustituidas con 6-ciclimetilo y 6-alquilmetilo
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
PA8649901A1 (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
IL164464A0 (en) Antagonists to mcp proteins, their preparation, pharmaceutical composition containing them, and their use
EP2332526A3 (de) Kombination eines Renin-Inhibitors mit einem anti-dyslipidämischen Wirkstoff oder einem Wirkstoff gegen Adipositas
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
DE602004012593D1 (de) Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
HRP20050713A2 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
IL173004A0 (en) Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments
DE602004022420D1 (de) Pharmazeutische zusammensetzungen, die cyclische somatostatinanaloga enthalten
TW200640858A (en) Substituted pyrroles, compositions containing them, method of manufacture and use
WO2004043463A3 (en) Sulfonamides
MXPA05010957A (es) Derivados de ornitina activos farmaceuticamente, sales de amonio de los mismos y metodos para su preparacion.
WO2005034873A3 (en) A method for reducing anti-neoplastic agent induced side-effects
ATE460421T1 (de) Phosphinsäurederivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1682122

Country of ref document: EP

RZN Patent revoked